- Home
- REPL vs AUTL Comparison
REPL vs AUTL Comparison
Compare REPL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- AUTL
- Stock Information
- Founded
- REPL 2015
- AUTL 2014
- Country
- REPL United States
- AUTL United Kingdom
- Employees
- REPL N/A
- AUTL N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REPL Health Care
- AUTL Health Care
- Exchange
- REPL Nasdaq
- AUTL Nasdaq
- Market Cap
- REPL 547.0M
- AUTL 625.4M
- IPO Year
- REPL 2018
- AUTL 2018
- Fundamental
- Price
- REPL $5.80
- AUTL $1.38
- Analyst Decision
- REPL Hold
- AUTL Strong Buy
- Analyst Count
- REPL 9
- AUTL 5
- Target Price
- REPL $7.00
- AUTL $9.12
- AVG Volume (30 Days)
- REPL 2.5M
- AUTL 4.4M
- Earning Date
- REPL 11-11-2025
- AUTL 11-11-2025
- Dividend Yield
- REPL N/A
- AUTL N/A
- EPS Growth
- REPL N/A
- AUTL N/A
- EPS
- REPL N/A
- AUTL N/A
- Revenue
- REPL N/A
- AUTL $29,934,000.00
- Revenue This Year
- REPL N/A
- AUTL $634.25
- Revenue Next Year
- REPL $408.25
- AUTL $93.16
- P/E Ratio
- REPL N/A
- AUTL N/A
- Revenue Growth
- REPL N/A
- AUTL 185.17
- 52 Week Low
- REPL $2.68
- AUTL $1.11
- 52 Week High
- REPL $17.00
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- REPL 47.90
- AUTL 28.28
- Support Level
- REPL $5.74
- AUTL $1.34
- Resistance Level
- REPL $6.15
- AUTL $1.46
- Average True Range (ATR)
- REPL 0.35
- AUTL 0.09
- MACD
- REPL 0.12
- AUTL 0.01
- Stochastic Oscillator
- REPL 41.03
- AUTL 9.09
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.